Anti-PD-1 scFv h(CD8-CD3ζ) CART, pCDCAR1
- 1.00 Dollar US$
- Published date: February 8, 2018
-
- Shirley, New York, United States
https://www.creative-biolabs.com/car-t/pcdcar1-pd-1-h-8ζ-t-474.htm The vector of anti-PD-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human PD-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PD-1 antibody linked to a CD8 hinge-transmembrane domain and CD3-zeta signaling domains. And the vector product was designed for the treatment of B-cell malignancies.










Useful information
- Avoid scams by acting locally or paying with PayPal
- Never pay with Western Union, Moneygram or other anonymous payment services
- Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
- This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"
Related listings
-
Anti-PD-1 scFv h(CD4-CD3ζ) CART, pCDCAR1
Drug Development Shirley (New York) February 8, 2018 1.00 Dollar US$https://www.creative-biolabs.com/car-t/pcdcar1-pd-1-h-4ζ-t-473.htm The vector of anti-PD-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human PD-1. The T cells are genetically modified through transduction w...
-
Anti-CD22 scFv h(CD8-CD3ζ) CART, pCDCAR1
Drug Development Shirley (New York) February 8, 2018 1.00 Dollar US$https://www.creative-biolabs.com/car-t/pcdcar1-cd22-h-8ζ-t-104.htm The vector of anti-CD22 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD22. The T cells are genetically modified through transduction w...
-
Anti-PD-1 scFv h(CD28-CD3ζ) CART, pCDCAR1
Drug Development Shirley (New York) February 8, 2018 1.00 Dollar US$https://www.creative-biolabs.com/car-t/pcdcar1-pd-1-h-28ζ-t-471.htm The vector of anti-PD-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human PD-1. The T cells are genetically modified through transduction ...